AstraZeneca (AZN), Merck (MRK) Enter Collaboration on Cancer Drug Lynparza; Will Receive $1.6B Upfront and Up to $8.5B

July 27, 2017 5:58 AM

AstraZeneca (NYSE: AZN) and Merck & Co., Inc., (NYSE: MRK) today announced that they have entered a global strategic oncology ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found